Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas Article

Villalona, MA, Bekaii-Saab, T, Burak, W et al. (2005). Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas . JOURNAL OF CLINICAL ONCOLOGY, 23(16_suppl), 4027-4027. 10.1200/jco.2005.23.16_suppl.4027

cited authors

  • Villalona, MA; Bekaii-Saab, T; Burak, W; Ross, P; Xu, Y; Criswell, T; Duan, W; Young, D; Miller, J; Kolesar, J

authors

publication date

  • June 1, 2005

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 4027

end page

  • 4027

volume

  • 23

issue

  • 16_suppl